Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
Clotblog with Dr Samuel Goldhaber
View all posts »CHA2DS2-VASc: Fine-tuning prediction of stroke risk
Jul 22, 2011 12:55 EDT-
1Comments
-
Read later
Recently endorsed by both the ESC and HRS, the CHA2DS2-VASc scoring system is more precisely predictive of stroke risk—compared with the older CHADS2 score—for patients with nonvalvular atrial fibrillation.
Have you adopted CHA2DS2-VASc in your practice?
See:
Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342:d124. Available here.
Lip GYH, Halperin J, Tse HF. The 2010 European Society of Cardiology Guidelines on the Management of Atrial Fibrillation: An evolution or revolution? [editorial] Chest 2011; 139:738-741. Available here.
Lip GYH. Implications of the CHADS-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillation. Am J Med 2011; 124:111-114. Abstract.
CHA2DS2-VASc: A new score for stroke prediction in AF
Adopting the CHA2DS2-VASc score. Or not.
Your comments
 |
 |
 |
||
 |
|
 |
||
 |
 |
 |
||
 |
|
|
 |
|
 |
 |
 |
||
 |
|
|
 |
|
|
|
|
||
|
||||
You must be a member (with full membership) to post a comment.
Already a member?
Enjoy all the benefits of theheart.org
With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.
Membership is free!
